United States Drug Eluting Stents Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Leander, Texas, United States - Nov. 17. 2025 The Global Drug Eluting Stents Market reached USD 6.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 10.2 billion by 2031. The global drug eluting stents market is expected to exhibit a CAGR of 6.4% during the forecast period (2024-2031).

Key Development:

United States: Recent Drug‐Eluting Stent Developments

✅ In September 2025, Boston Scientific received FDA approval for its TAXUS® Express2TM AtomTM paclitaxel‐eluting coronary stent, designed for very small vessels (as small as 2.25 mm), addressing a previously unmet need.

✅ In July 2025, Boston Scientific reinforced the importance of its two‐drug DES strategy after gaining traction for the PROMUSTM everolimus‐eluting stent system, strengthening its differentiated portfolio.

✅ In May 2025, Medtronic's Onyx FrontierTM DES (from its Resolute family) with enhanced deliverability (dual‐layer balloon, flexible catheter) continued to influence physician adoption, thanks to its design evolution.

✅ In recent years, Biotronik's Orsiro Mission bioabsorbable‐polymer DES remains one of the thinnest‐strut stents available in the U.S., combining high deliverability and strong clinical data.

Japan: Recent Drug‐Eluting Stent Developments

✅ In September 2025, Japan's regulatory framework incorporated discussions on next‐generation DES with bio‐absorbable polymers and ultra-thin struts, as highlighted in sessions of the Japanese Circulation Society.

✅ In March 2025, the Japanese regulatory body granted manufacturing and marketing approval for a domestically developed absorbable esophageal stent ("ELLA‐BD PX") by Pylorax Medical Devices, marking the first of its kind in Japan.

✅ In 2025, Japan's PMDA approved a stent system (Fukuda‐Electronics' "Cardimax FCP‐9800 Ai") that includes a drug‐coated coronary DES component with anti‐CD34 antibody plus sirolimus, reflecting innovation in endothelial-progenitor‐cell capturing DES.

✅ In 2025, health‐insurance policy changes in Japan introduced reimbursement for a steroid‐coated absorbable sinus stent (PROPELTM), classifying it under "drug‐eluting absorbable stent" with new fee schedules and proper use guidance.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/drug-eluting-stents-market?sb

Key Players:

=> Boston Scientific Corp., Abbott Laboratories, Medtronic Plc, Biotronik Inc., Johnson & Johnson, MicroPort Scientific Corporation, Cook Medical Inc., Stentys S.A., Biosensors International Group, and Terumo Corp., among others.

Growth Drivers of Drug-Eluting Stents:

✅ Rising Cardiovascular Disease Incidence: Increasing cases of coronary artery disease (CAD) and heart-related conditions globally.

✅ Advancements in Stent Technology: Introduction of bioresorbable scaffolds, drug-coated stents, and nanotechnology-based coatings enhancing safety and efficacy.

✅ Aging Population: Growing geriatric population with higher prevalence of cardiovascular issues driving demand for stent procedures.

✅ Preference for Minimally Invasive Procedures: DES offers lower risk and faster recovery compared to open-heart surgeries, boosting adoption.

✅ Rising Awareness and Early Diagnosis: Improved screening and early detection of CAD supporting timely interventions with DES.

✅ Healthcare Infrastructure Expansion: Increasing hospital facilities and cardiac centers, especially in emerging economies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=drug-eluting-stents-market

Key Segments:

By Coating

Polymer-based coating stents: Includes non-biodegradable polymer stents with proven long-term safety and biodegradable polymer stents that reduce inflammation and late-stage thrombosis risk. Biodegradable polymer stents are gaining traction due to improved vascular healing and regulatory approvals.

Polymer-free coating stents: Emerging segment aimed at patients with polymer hypersensitivity or high bleeding risk. Offers safer outcomes in niche patient populations and is expected to witness steady growth over the forecast period.

By Application

Coronary Artery Diseases (CAD): The largest application segment driven by the rising prevalence of CAD, increasing percutaneous coronary interventions (PCI), and aging populations. DES adoption is expanding for complex and multi-vessel cases.

Peripheral Artery Disease (PAD): Includes femoral, popliteal, and renal artery interventions. Growth is supported by rising PAD incidence, diabetes prevalence, and demand for minimally invasive treatment options.

By End-User

Hospitals: The dominant end-user, with advanced cath labs and PCI facilities enabling high-volume DES adoption.

Ambulatory Surgical Centers (ASCs): Increasingly preferred for elective stenting procedures, particularly in stable CAD cases. Cost-effective and quicker procedures drive adoption.

Cardiac Centers: Specialized centers handling high-risk or complex CAD cases. Adoption of advanced DES technologies is concentrated here.

Regional Analysis

North America (≈34% share)
The U.S. leads due to high CAD prevalence, mature healthcare infrastructure, and early adoption of polymer-based and polymer-free DES. Canada emphasizes minimally invasive interventions and rising DES adoption in hospitals and cardiac centers. Favorable reimbursement policies and strong R&D drive market expansion.

Europe (≈28% share)
Germany, France, and the U.K. lead adoption due to high CAD incidence and aging populations. Northern and Southern Europe are witnessing increased use of biodegradable polymer DES. Stringent regulatory approvals ensure high-quality products but slow rapid commercialization.

Asia-Pacific (≈26% share)
China, Japan, and India are expanding DES adoption rapidly due to increasing cardiovascular disease burden, growing hospital infrastructure, and government health initiatives. Preference is increasing for polymer-free and biodegradable polymer DES in urban healthcare centers.

Latin America (≈6% share)
Brazil, Mexico, and Argentina are gradually adopting DES in major hospitals. Urban centers drive growth, but infrastructure limitations outside large cities constrain broader penetration. Partnerships with international DES manufacturers are improving access.

Middle East & Africa (≈6% share)
UAE, Saudi Arabia, and South Africa lead adoption in tertiary hospitals and specialized cardiac centers. Government initiatives and smart healthcare investments are supporting growth. Smaller hospitals still face adoption challenges due to cost and infrastructure gaps.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/drug-eluting-stents-market?sb

FAQ

What is the current size of the Drug Eluting Stents Market?

A: In 2022, the Drug Eluting Stents Market was valued at USD 6.3 billion , reflecting its strong industry presence.

Q2: How large is the Drug Eluting Stents Market expected to be by 2031?

A: By 2031, industry forecasts suggest the Drug Eluting Stents Market will grow to around USD 10.2 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Drug Eluting Stents Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6.4% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.